Last reviewed 2026-05-28 · How we verify

Placebo Tablet and Nicotine Patch

Placebo Tablet and Nicotine Patch is a Nicotine replacement therapy (NRT) Small molecule drug developed by The Scripps Research Institute. It is currently FDA-approved for Smoking cessation / nicotine dependence. Also known as: Nicotrol.

Nicotine from the patch binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation, while the placebo tablet serves as a control comparator.

Placebo tablets are used in clinical trials for smoking cessation, tobacco use cessation, and nicotine addiction. Nicotine patches are not mentioned in the provided facts, but Placebo tablets are used alongside varenicline tartrate and bupropion hydrochloride in clinical trials for smoking cessation.

At a glance

Mechanism of action

Nicotine is a psychoactive alkaloid that acts as an agonist at nicotinic acetylcholine receptors, particularly in the ventral tegmental area and nucleus accumbens, reinforcing reward pathways and reducing the discomfort of nicotine withdrawal. The placebo tablet component is used in clinical trials to establish the efficacy of nicotine replacement therapy above baseline. This combination is typically used in research settings to evaluate the comparative effectiveness of nicotine patch therapy for smoking cessation.

Approved indications

• Smoking cessation / nicotine dependence

Common side effects

• Skin irritation at patch application site
• Nausea
• Headache
• Dizziness
• Sleep disturbances
• Palpitations

Key clinical trials

• Reward Sensitivity and Pharmacotherapy for Smoking Cessation (PHASE4)
• Varenicline and Combined NRT for Smoking Cessation (PHASE4)
• Effect of Nicotine Transdermal Patch on Cognitive Function and Glycolipid Metabolism in Non-smoking Schizophrenia (EARLY_PHASE1)
• Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation (PHASE4)
• Multimodal Cue Exposure Therapy for Smoking Cessation (PHASE2)
• Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) (PHASE4)
• Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders (PHASE4)
• Pharmacogenetics of Nicotine Addiction Treatment (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Placebo Tablet and Nicotine Patch CI brief — competitive landscape report
• Placebo Tablet and Nicotine Patch updates RSS · CI watch RSS
• The Scripps Research Institute portfolio CI

Frequently asked questions about Placebo Tablet and Nicotine Patch

Related

• Drug class: All Nicotine replacement therapy (NRT) drugs
• Target: All drugs targeting Nicotinic acetylcholine receptors
• Manufacturer: The Scripps Research Institute — full pipeline
• Therapeutic area: All drugs in Addiction Medicine / Smoking Cessation
• Indication: Drugs for Smoking cessation / nicotine dependence
• Also known as: Nicotrol

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing